TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search results
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search results
Obesity may weaken vaccine protection: study
Among those in the study without previous SARS-CoV-2 infection who had received the Pfizer vaccine, patients with severe obesity had antibody levels more than three times lower than normal-weight individuals.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
In this June 26, 2012 file photo, two women converse in New York. The nation's obesity epidemic continues to grow, led by an alarming increase among women. For the first time, more than 4 in 10 U.S. women are obese, according to statistics released by the Centers for Disease Control and Prevention on Tuesday, June 7, 2016. (AP Photo/Mark Lennihan)
S
evere obesity may weaken the effectiveness of COVID-19 vaccines in those who have never been infected with the coronavirus, according to a small Turkish study.
Among those in the study without previous SARS-CoV-2 infection who had received the Pfizer vaccine, patients with severe obesity had antibody levels more than three times lower than normal-weight individuals.
Among recipients of Sinovac Biotech's CoronaVac, those with severe obesity and no history of prior infection had antibody levels 27 times lower than normal weight people, according to data being presented this week at the European Congress on Obesity in Maastricht, Netherlands. By comparison, in the 70 volunteers with a previous coronavirus infection, antibody levels were similar in people with and without severe obesity.
For the study, researchers had compared immune responses to vaccines in 124 volunteers with severe obesity - defined as a body mass index of 40 or higher - and 166 normal-weight individuals (BMI less than 25). Overall, 130 participants had received two doses of the Pfizer/BioNTech mRNA vaccine and 160 had received two doses of Sinovac's inactivated-virus vaccine.
While two doses of the Pfizer/BioNTech vaccine "may generate significantly more antibodies than CoronaVac in people with severe obesity... further research is needed to determine whether these higher antibody levels provide greater protection against COVID-19," study leader Volkan Demirhan Yumuk from Istanbul University said in a statement
More from The Weekender
Jakarta’s padel moment
From FOMO to full-blown obsession, padel has captured the city. What comes next may depend less on courts and more on the communities that grow around them.
The battle over memory
And why the government’s plan to rewrite its history books should alarm us all.
Are younger workers getting something right about work?
As micro-retirements gain traction, Gen Z and young millennials are challenging traditional ideas of ambition, success and when it’s okay to pause.
